{"id":"tocilizumab-iv","safety":{"boxedWarning":"Serious infections leading to hospitalization or death including tuberculosis, bacterial, invasive fungal, viral and other opportunistic infections have occurred. Discontinue if serious infection develops. Test for latent tuberculosis before initiating therapy.","commonSideEffects":["Upper respiratory tract infections","Nasopharyngitis","Headache","Hypertension","Increased ALT"],"contraindications":["Active serious infections"]},"_chembl":{"chemblId":"CHEMBL1237022","moleculeType":"Antibody"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"IL-6 receptor","explanation":"Tocilizumab is a humanized monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling. By blocking this pathway, it reduces the inflammatory cascade involved in autoimmune and inflammatory diseases.","oneSentence":"Tocilizumab binds to IL-6 receptors, blocking interleukin-6 signaling and reducing inflammation."},"_scrapedAt":"2026-03-28T01:39:09.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122777,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"sarilumab","brand":"Kevzara","company":"Sanofi/Regeneron","rationale":"IL-6 receptor antagonist for rheumatoid arthritis"},{"name":"adalimumab","brand":"Humira","company":"AbbVie","rationale":"TNF inhibitor for rheumatoid arthritis and autoimmune conditions"},{"name":"baricitinib","brand":"Olumiant","company":"Eli Lilly","rationale":"JAK inhibitor for rheumatoid arthritis"},{"name":"rituximab","brand":"Rituxan","company":"Roche","rationale":"Monoclonal antibody for rheumatoid arthritis after TNF failure"}],"description":"Tocilizumab IV is a monoclonal antibody developed by Hoffmann-La Roche that blocks the interleukin-6 (IL-6) receptor. It is used to treat various inflammatory and autoimmune conditions including rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome. The intravenous formulation allows for controlled dosing in hospital and clinic settings.","indications":{"approved":[{"status":"approved","condition":"Rheumatoid arthritis","patientPopulation":"Adult patients with moderately to severely active disease"},{"status":"approved","condition":"Giant cell arteritis","patientPopulation":"Adult patients"},{"status":"approved","condition":"Cytokine release syndrome","patientPopulation":"Adult and pediatric patients with CAR T-cell induced CRS"},{"status":"approved","condition":"Polyarticular juvenile idiopathic arthritis","patientPopulation":"Pediatric patients 2 years and older"},{"status":"approved","condition":"Systemic juvenile idiopathic arthritis","patientPopulation":"Pediatric patients 2 years and older"}]},"trialDetails":[{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT05233397","phase":"PHASE2","title":"ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-12-16","conditions":"Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma","enrollment":38},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05169515","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-26","conditions":"Non-Hodgkin Lymphoma","enrollment":121},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":126},{"nctId":"NCT04246086","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-12","conditions":"Follicular Lymphoma","enrollment":237},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06934044","phase":"PHASE1","title":"A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-13","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT03999749","phase":"PHASE2","title":"A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-06-11","conditions":"Melanoma","enrollment":71},{"nctId":"NCT05583617","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-14","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT05533775","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-16","conditions":"Mature B-Cell Non-Hodgkin Lymphoma","enrollment":65},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT05927571","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-08-10","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":120},{"nctId":"NCT03075696","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-02-21","conditions":"Non-Hodgkin's Lymphoma","enrollment":940},{"nctId":"NCT06624085","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-28","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT06863480","phase":"PHASE1","title":"Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03-02","conditions":"Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia","enrollment":30},{"nctId":"NCT05091424","phase":"PHASE1","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":137},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":"Lymphoma","enrollment":182},{"nctId":"NCT04077723","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-13","conditions":"Lymphoma, Non-Hodgkin","enrollment":498},{"nctId":"NCT07108387","phase":"PHASE2","title":"Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-11","conditions":"Giant Cell Arteritis (GCA)","enrollment":78},{"nctId":"NCT03448042","phase":"PHASE1","title":"A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2018-06-06","conditions":"Solid Tumors","enrollment":123},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT05391750","phase":"PHASE1","title":"Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":7},{"nctId":"NCT04412772","phase":"PHASE3","title":"Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-06-12","conditions":"COVID-19","enrollment":20},{"nctId":"NCT05535244","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-17","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT04375228","phase":"PHASE2","title":"Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2020-09-25","conditions":"Immune-related Adverse Events, Advanced Solid Tumor","enrollment":8},{"nctId":"NCT04712097","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-27","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":478},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT03869190","phase":"PHASE1, PHASE2","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-01","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":272},{"nctId":"NCT05070247","phase":"PHASE1, PHASE2","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Takeda","startDate":"2022-04-14","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma","enrollment":61},{"nctId":"NCT05846789","phase":"PHASE2","title":"SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers","status":"RECRUITING","sponsor":"Kathy Miller","startDate":"2024-07-02","conditions":"Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer","enrollment":168},{"nctId":"NCT07254637","phase":"PHASE2","title":"Tocilizumab in Chronic Inflammatory CPPD Disease","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Calcium Pyrophosphate Deposition Disease","enrollment":80},{"nctId":"NCT07334379","phase":"PHASE2","title":"Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study","status":"RECRUITING","sponsor":"Lorenzo delSorbo","startDate":"2025-10-20","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":60},{"nctId":"NCT04408638","phase":"PHASE3","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":270},{"nctId":"NCT04691817","phase":"PHASE1, PHASE2","title":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-07-25","conditions":"Lung Cancer, Nonsmall Cell","enrollment":28},{"nctId":"NCT04616248","phase":"PHASE1","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-01-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":14},{"nctId":"NCT04395222","phase":"PHASE2","title":"Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-07","conditions":"Hematologic Malignancy, Bone Marrow Transplant","enrollment":21},{"nctId":"NCT03533283","phase":"PHASE1, PHASE2","title":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-05-08","conditions":"Non-Hodgkins Lymphoma","enrollment":211},{"nctId":"NCT07281027","phase":"PHASE3","title":"COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03-01","conditions":"New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)","enrollment":438},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT05364424","phase":"PHASE1","title":"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-11-04","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":43},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT01791842","phase":"PHASE2","title":"TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-05-05","conditions":"Fibrous Dysplasia of Bone","enrollment":19},{"nctId":"NCT01673919","phase":"PHASE3","title":"A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Juvenile Idiopathic Arthritis","enrollment":7},{"nctId":"NCT04007029","phase":"PHASE1","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-04","conditions":"CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT03677154","phase":"PHASE1, PHASE2","title":"Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-05-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":188},{"nctId":"NCT05350592","phase":"PHASE2","title":"Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-03-13","conditions":"Acute Myocardial Infarction, Cardiogenic Shock","enrollment":100},{"nctId":"NCT05168475","phase":"PHASE2","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-07-14","conditions":"Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome","enrollment":22},{"nctId":"NCT03821246","phase":"PHASE2","title":"Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy","status":"RECRUITING","sponsor":"David Oh","startDate":"2019-10-30","conditions":"Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer","enrollment":68},{"nctId":"NCT04363853","phase":"PHASE2","title":"Tocilizumab Treatment in Patients With COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2020-06-01","conditions":"Sars-CoV2","enrollment":200},{"nctId":"NCT05067348","phase":"PHASE2","title":"Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2022-07-21","conditions":"Myasthenia Gravis, Generalized","enrollment":64},{"nctId":"NCT05155345","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-01-11","conditions":"Systemic Lupus Erythematosus","enrollment":15},{"nctId":"NCT02765074","phase":"PHASE4","title":"Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2016-06-30","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT05640271","phase":"PHASE2","title":"Tocilizumab for Acute Chest Syndrome","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-04-10","conditions":"Sickle Cell Disease, Acute Chest Syndrome","enrollment":200},{"nctId":"NCT04370834","phase":"PHASE2","title":"Tocilizumab for Patients With Cancer and COVID-19 Disease","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-28","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia","enrollment":1},{"nctId":"NCT03708224","phase":"PHASE2","title":"Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck","status":"RECRUITING","sponsor":"Alain Algazi","startDate":"2019-03-08","conditions":"Cancer, Carcinoma, Squamous Cell Carcinoma","enrollment":55},{"nctId":"NCT03467373","phase":"PHASE1","title":"A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-03-13","conditions":"B-Cell Lymphoma, Non-Hodgkin Lymphoma","enrollment":111},{"nctId":"NCT03677141","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-03-08","conditions":"B-cell Non-Hodgkin Lymphoma","enrollment":117},{"nctId":"NCT04338685","phase":"PHASE1","title":"A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-16","conditions":"Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer","enrollment":55},{"nctId":"NCT03671018","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-25","conditions":"B-cell Non-Hodgkin Lymphoma","enrollment":422},{"nctId":"NCT04652258","phase":"PHASE2","title":"Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2021-02-01","conditions":"Pyrexia","enrollment":20},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT05489224","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-09-14","conditions":"Rheumatoid Arthritis","enrollment":471},{"nctId":"NCT05315713","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-10","conditions":"Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":8},{"nctId":"NCT06372574","phase":"PHASE1","title":"A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors","status":"WITHDRAWN","sponsor":"Genentech, Inc.","startDate":"2024-09-30","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":""},{"nctId":"NCT05219513","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-02-18","conditions":"Lymphoma, Non-Hodgkin","enrollment":53},{"nctId":"NCT03866239","phase":"PHASE1","title":"A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2019-05-07","conditions":"Colorectal Cancer","enrollment":47},{"nctId":"NCT02049437","phase":"PHASE1, PHASE2","title":"AIDS 347: IL-6 Blockade in Treated HIV Infection","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2014-08","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT04580121","phase":"PHASE1","title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-11-04","conditions":"Acute Myeloid Leukemia","enrollment":59},{"nctId":"NCT05164133","phase":"PHASE1","title":"A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-06-10","conditions":"COVID-19","enrollment":2},{"nctId":"NCT04313608","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-06-04","conditions":"B-cell Lymphoma","enrollment":23},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT03301883","phase":"PHASE4","title":"A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-26","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT05716035","phase":"PHASE2, PHASE3","title":"Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2023-04-01","conditions":"Myasthenia Gravis, Generalized","enrollment":64},{"nctId":"NCT04657302","phase":"PHASE1","title":"A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-01-08","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT05833763","phase":"PHASE2","title":"A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.","status":"RECRUITING","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2023-10-12","conditions":"Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory","enrollment":42},{"nctId":"NCT01664598","phase":"PHASE3","title":"An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT05963048","phase":"PHASE2, PHASE3","title":"Rituxmab Versus IL-6 in Treating ILD","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-12-01","conditions":"Interstitial Lung Disease, Scleroderma","enrollment":60},{"nctId":"NCT06048224","phase":"PHASE3","title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2020-12-28","conditions":"Moderate to Severe Active Rheumatoid Arthritis","enrollment":669},{"nctId":"NCT04321993","phase":"PHASE2","title":"Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","status":"UNKNOWN","sponsor":"Lisa Barrett","startDate":"2020-04-17","conditions":"COVID-19","enrollment":363},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT02511067","phase":"PHASE2","title":"Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-10-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT05129280","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-01-25","conditions":"Solid Tumors","enrollment":23},{"nctId":"NCT03699631","phase":"PHASE2","title":"PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-11-06","conditions":"Hematologic Malignancy","enrollment":29},{"nctId":"NCT04330638","phase":"PHASE3","title":"Treatment of COVID-19 Patients With Anti-interleukin Drugs","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-04-03","conditions":"COVID-19","enrollment":342},{"nctId":"NCT03467256","phase":"PHASE1, PHASE2","title":"CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2018-05-14","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric","enrollment":18},{"nctId":"NCT04688021","phase":"PHASE2","title":"A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.","status":"UNKNOWN","sponsor":"Yi Luo","startDate":"2020-12-03","conditions":"Leukemia, Graft-versus-host-disease","enrollment":46},{"nctId":"NCT04372186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2020-05-14","conditions":"COVID-19 Pneumonia","enrollment":377},{"nctId":"NCT05277285","phase":"PHASE2","title":"STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care","status":"UNKNOWN","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2022-04-01","conditions":"COVID-19, Virus Diseases, Corona Virus Infection","enrollment":30},{"nctId":"NCT04551352","phase":"PHASE1","title":"A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma","enrollment":20},{"nctId":"NCT04363736","phase":"PHASE2","title":"A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-05","conditions":"COVID-19 Pneumonia","enrollment":97},{"nctId":"NCT04734678","phase":"","title":"Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-12-01","conditions":"Covid19, Cytokine Storm, Corona Virus Infection","enrollment":153}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"RESPIRATORY FAILURE"},{"count":1,"reaction":"ACIDOSIS"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"BRADYCARDIA"},{"count":1,"reaction":"HYPERNATRAEMIA"},{"count":1,"reaction":"HYPERTRIGLYCERIDAEMIA"},{"count":1,"reaction":"LEUKOCYTOSIS"},{"count":1,"reaction":"RENAL IMPAIRMENT"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RoActemra/Actemra"],"phase":"phase_3","status":"active","brandName":"tocilizumab IV","genericName":"tocilizumab IV","companyName":"Hoffmann-La Roche","companyId":"roche","firstApprovalDate":"","aiSummary":"Tocilizumab IV is an interleukin-6 receptor alpha subunit inhibitor, classified as an INHIBITOR drug modality. It is used to treat various conditions, including Diffuse Large B-Cell Lymphoma (DLBCL), and is being studied for its efficacy in Generalized Myasthenia Gravis, among other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}